Panel is a valuable tool for hypothesis generation and testing. BRAF is the most common melanoma mutation. Findings validate patient-derived tumor models. SAN FRANCISCO — Researchers have developed a new genetic screening tool that will aid in the investigation of possible treatments for patients...
Posted to
News
by
AACR News
on
Tue, Nov 15 2011
Filed under:
Filed under: Press Releases, Research, Treatment, Conference, melanoma, Cancer, Media Materials, AACR, American Association for Cancer Research, mutations, genetics, screening, meeting, National Cancer Institute, NCI, skin cancer, Molecular Targets, AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Cancer Therapeutics, EORTC, European Organisation for Research and Treatment of Cancer, panel, Dr. Heinz-Herbert Fiebig
Aggressive lung cancers harboring KRAS mutations are sensitive to antifolates. Antifolates decrease KRAS gene expression. Large clinical trials needed to investigate antifolate effects in cancers with respect to driving mutations. SAN FRANCISCO — Patients with non-small cell lung cancer who have...
Posted to
News
by
AACR News
on
Sun, Nov 13 2011
Filed under:
Filed under: Press Releases, Research, Treatment, Conference, Cancer, Media Materials, AACR, lung cancer, American Association for Cancer Research, mutations, meeting, National Cancer Institute, NCI, KRAS, non-small cell lung cancer, Molecular Targets, AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Cancer Therapeutics, EORTC, European Organisation for Research and Treatment of Cancer, pemetrexed, antifolates, methotrexate, Dr. Sarah Bacus
Recently discovered BRAF inhibitors may prevent drug-induced skin lesion side effects and lead to greater treatment durability. Mechanism of drug-induced skin lesions is explored in preclinical model. SAN FRANCISCO — Findings from preclinical studies in a skin cancer model showed that next-generation...
Posted to
News
by
AACR News
on
Sun, Nov 13 2011
Filed under:
Filed under: Press Releases, Research, Treatment, Conference, melanoma, Cancer, Media Materials, AACR, American Association for Cancer Research, meeting, National Cancer Institute, NCI, skin cancer, EGFR, Molecular Targets, AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Cancer Therapeutics, EORTC, European Organisation for Research and Treatment of Cancer, preclinical studies, Dr. Gideon Bollag, oncogenes, BRAF
Shutting down the ALK-1 receptor inhibits the VEGF pathway. Response seen in patients who had used antiangiogenic therapy. VEGF therapies might work best in combination. SAN FRANCISCO — Despite the widespread use of current antiangiogenic cancer therapies, many tumors escape this blockade, which...
Posted to
News
by
AACR News
on
Sun, Nov 13 2011
Filed under:
Filed under: Press Releases, Research, Treatment, Conference, Cancer, Media Materials, AACR, American Association for Cancer Research, meeting, National Cancer Institute, NCI, tumor suppressor, angiogenesis, Molecular Targets, AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Cancer Therapeutics, EORTC, metastasis, European Organisation for Research and Treatment of Cancer, Dr. Filippo de Braud, antiangiogenesis, monoclonal antibody, VEGF therapy
Phenotypic platform better predicts cancer drug effectiveness from the lab to actual tumors. Platform reduces time and money spent on drugs that will not work or will be toxic. Platform removes researcher bias in choosing systems to target for drug discovery. SAN FRANCISCO — Researchers have created...
Posted to
News
by
AACR News
on
Sun, Nov 13 2011
Filed under:
Filed under: Press Releases, Research, Treatment, Conference, Cancer, Media Materials, AACR, American Association for Cancer Research, meeting, Drug discovery, National Cancer Institute, NCI, angiogenesis, Molecular Targets, AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Cancer Therapeutics, EORTC, European Organisation for Research and Treatment of Cancer, antiangiogenesis, phenotypic platform, Dr. Enrique Zudaire, cancer drug
VEGF and Ang2 are critical factors required for tumor angiogenesis. Combined blockade of VEGF and Ang2 with investigational agents enhances antitumor activity in preclinical studies. Combination of REGN910 with aflibercept warrants further clinical investigation. SAN FRANCISCO — Combining the investigational...
Posted to
News
by
AACR News
on
Sun, Nov 13 2011
Filed under:
Filed under: Press Releases, Research, Treatment, Conference, Cancer, Media Materials, AACR, American Association for Cancer Research, meeting, National Cancer Institute, NCI, angiogenesis, Molecular Targets, AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Cancer Therapeutics, EORTC, European Organisation for Research and Treatment of Cancer, antiangiogenesis, antitumor, Ang2, Dr. Alshad S. Lalani, REGN910, aflibercept, combination therapy, VEGF, preclinical studies
Findings represent first evidence of ALK activity in inflammatory breast cancer. Data emphasize importance of proteins and enzymes to define molecular biology. Identification of ALK pathway activation could allow for more targeted treatment. SAN FRANCISCO — Amplification of anaplastic lymphoma...
Posted to
News
by
AACR News
on
Sun, Nov 13 2011
Filed under:
Filed under: Press Releases, Research, Treatment, Breast Cancer, Conference, Cancer, Media Materials, AACR, American Association for Cancer Research, meeting, National Cancer Institute, NCI, Molecular Targets, AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Cancer Therapeutics, EORTC, metastasis, European Organisation for Research and Treatment of Cancer, Dr. Fredika M. Robertson, inflammatory breast cancer, anaplastic lymphoma kinase, ALK, Dr. Massimo Cristofanilli
HDAC inhibitor with tamoxifen treatment reduced tumor cell resistance in estrogen receptor-positive breast cancer. Critical pathway by which tumors become tamoxifen resistant identified. Early introduction of HDAC inhibitor with tamoxifen is key. SAN FRANCISCO — Researchers have shown how estrogen...
Posted to
News
by
AACR News
on
Sun, Nov 13 2011
Filed under:
Filed under: Press Releases, Research, Treatment, Breast Cancer, Conference, Cancer, Media Materials, AACR, American Association for Cancer Research, meeting, National Cancer Institute, NCI, estrogen receptor-positive breast cancer, Molecular Targets, AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Cancer Therapeutics, EORTC, European Organisation for Research and Treatment of Cancer, HDAC inhibitor, tamoxifen, ER-positive breast cancer, AKT, Dr. Pamela N. Munster
HDAC inhibitor first to show benefit in a controlled study in breast cancer. Protein lysine acetylation linked to longer disease-free survival. Study shows clinical gain can be determined after first or second dose of entinostat. SAN FRANCISCO — Clinical benefit from use of a novel histone...
Posted to
News
by
AACR News
on
Sun, Nov 13 2011
Filed under:
Filed under: Press Releases, Research, Treatment, Breast Cancer, Conference, Cancer, Media Materials, AACR, American Association for Cancer Research, meeting, National Cancer Institute, NCI, AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, EORTC, entinostat, European Organisation for Research and Treatment of Cancer, histone deacetylase inhibitor, Dr. Peter Ordentlich, blood cell assays, protein lysine acetylation, HDAC
SAN FRANCISCO — Progress in oncology drug development will take center stage Nov. 12-16, 2011, as thousands of scientists and industry experts convene at the Moscone Center West in San Francisco for the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics. “During the last...
Posted to
News
by
AACR News
on
Thu, Nov 10 2011
Filed under:
Filed under: Press Releases, San Francisco, Research, Treatment, Breast Cancer, Conference, Cancer, teleconference, Media Materials, AACR, American Association for Cancer Research, Clinical Cancer Research, meeting, National Cancer Institute, NCI, angiogenesis, AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, EORTC, Dr. Kenneth C. Anderson, European Organisation for Research and Treatment of Cancer, Dr. James H. Doroshow, Moscone Center West
SAN FRANCISCO – The American Association for Cancer Research announces the following embargo policy for the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, to be held in San Francisco Nov. 12-16, 2011. The policy states: Due to the high volume of sensitive fiduciary...
Posted to
News
by
AACR News
on
Wed, Oct 12 2011
Filed under:
Filed under: Press Releases, Policy, Research, Treatment, Conference, Cancer, Media Materials, AACR, American Association for Cancer Research, meeting, NCI, Molecular Targets, press policy, embargo, AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Cancer Therapeutics, EORTC, embargo policy